Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111)
. No severe vaso-occlusive events (VOEs) were reported through 24 months of follow up in Group C patients of the HGB-206…
. No severe vaso-occlusive events (VOEs) were reported through 24 months of follow up in Group C patients of the HGB-206…
JPK Instruments, a world-leading manufacturer of nanoanalytic instrumentation for research in life sciences and soft mat…